Study Design: A cross-sectional study of baseline correlates of clinical pain and functional status in consecutive patients being treated for chronic low back pain.
Objectives: To determine if an individual's global pain sensitivity, measured by experimental pain threshold to pressure at various regions of the body, is associated with baseline measures of clinical pain and physical functioning.
Summary Of Background Data: Previous studies have demonstrated that in individuals with chronic low back pain, clinical pain and functional status are significantly associated with demographic, structural, and psychosocial factors. However, a large portion of variance remains unexplained. Because pain sensitivity (tenderness) has been shown to occur as a continuum in the population, the authors sought to determine if such sensitivity might be associated with clinical status in chronic low back pain, beyond what is known regarding demographic, structural, and psychosocial factors.
Methods: Forty-five patients with chronic low back pain were assessed for a variety of demographic, structural, and psychosocial factors, which previously have been shown to contribute to clinical status. In addition, all patients underwent testing for pain tolerance and threshold at various areas of the body.
Results: Age, degree of structural abnormality observed on magnetic resonance imaging, and depressive symptoms were all significantly correlated with either clinical pain or functional status. Pain sensitivity, the target of this investigation, accounted for significant proportions of variance in functional status and pain, even after controlling for demographic, structural, and psychosocial variables.
Conclusions: These pilot data suggest that an individual's experimental pain threshold (a measure of tenderness) is associated with baseline functional status and pain in cases of chronic low back pain and may represent an important domain warranting further investigation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00007632-199910010-00013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Randomized comparison of a Gladius first versus standard antegrade wiring strategy for crossing coronary chronic total occlusions: the Gladius first trial.
J Invasive Cardiol
December 2024
Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland.
Objectives: Antegrade wiring (AW) is the most common coronary chronic total occlusion (CTO) crossing strategy and usually relies upon stepwise guidewire escalation starting from the low tip-load polymer-jacketed wire (standard guidewire escalation). The authors aimed to investigate whether the upfront use of intermediate tip-load polymer-jacketed guidewire translates into improved procedural outcomes of CTO percutaneous coronary intervention (PCI).
Methods: The Gladius First trial was a single-center, investigator-initiated, randomized, prospective trial.
Parent-Targeted Oral Health Text Messaging for Underserved Children Attending Pediatric Clinics: A Randomized Clinical Trial.
JAMA Netw Open
January 2025
Office of Global and Population Health, Boston University Henry M. Goldman School of Dental Medicine, Boston, Massachusetts.
Importance: Caries is the most common chronic childhood disease, with substantial health disparities.
Objective: To test whether parent-targeted oral health text (OHT) messages outperform child wellness text (CWT) messages on pediatric caries increment and oral health behaviors among underserved children attending pediatric well-child visits.
Design, Setting, And Participants: The parallel randomized clinical trial, Interactive Parent-Targeted Text Messaging in Pediatric Clinics to Reduce Caries Among Urban Children (iSmile), included participants who were recruited during pediatric medical clinic visits at 4 sites in Boston, Massachusetts, that serve low-income and racially and ethnically diverse (herein, underserved) populations.
Comparison of the characteristics of patients with chronic urticaria receiving standard- or high-dose omalizumab.
Eur Ann Allergy Clin Immunol
January 2025
Division of Allergy and Clinical Immunology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
In patients whose chronic urticaria (CU) cannot be controlled with omalizumab 300 mg and antihistamines, the dose can be increased up to 600 mg. The study aimed to compare the clinical characteristics of patients receiving 300 mg versus higher doses of omalizumab, and to evaluate baseline predictors for updosing. A total of 159 patients who have been followed up at a tertiary care allergy center and received omalizumab for at least 12 months were included.
View Article and Find Full Text PDFProvocation test on stairs: a new accessible method to cholinergic urticaria diagnosis.
Eur Ann Allergy Clin Immunol
January 2025
Immunology Service, Hospital Universitário Clementino Fraga Filho (HUCFF-UFRJ), Rio de Janeiro, Brazil.
Cholinergic urticaria (CholU) is characterized by itching and/or stinging, painful micro wheals due to systemic heating. There are two standardized protocols to diagnose CholU using an exercise bike with heart rate or warming passive. The objective is to provide an affordable, new, low-tech test to assist the diagnostic.
View Article and Find Full Text PDFIs Platelet-rich Plasma Effective in Treating Achilles Tendinopathy? A Meta-analysis of Randomized Clinical Trials.
Clin Orthop Relat Res
December 2024
Federal University of Bahia, Salvador, Brazil.
Background: Several meta-analyses have evaluated the use of platelet-rich plasma (PRP) in the treatment of Achilles tendinopathy. Although they generally did not find PRP to be effective, an updated meta-analysis containing all the available, high-quality randomized trial evidence that addresses the methodological shortcomings identified in earlier meta-analyses needs to be performed.
Question/purposes: This systematic review and meta-analysis aimed to evaluate the efficacy of PRP in improving (1) pain and function as assessed using the Victorian Institute of Sports Assessment-Achilles (VISA-A) score 3 months, 6 months, and 1 year after treatment and (2) VAS pain scores 3 months after treatment in patients with chronic Achilles tendinopathy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!